25 min.
Dr. Peter Westerweel selecteerde voor MEDtalks het belangrijkste ASH-nieuws over chronische myeloïde leukemie, waaronder een 'late breaker'.
Directe links naar de ASH-abstracts
Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed CML: Results of the Prospective Randomized Phase 3 Study, JALSG CML212
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib vs Bosutinib in Patients with CML-CP Previously Treated with ≥2 TKIs
Asciminib Provides Durable Molecular Response in Patients with CML Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial
COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study